Synairgen Collaboration Progress
Release Date: 13/03/2017 8:42am
Pharmaceutical research company Pharmaxis (ASX: PXS) is pleased to report progress from its ongoing collaboration with UK biotechnology company Synairgen plc (LSE: SNG) to develop a selective inhibitor to the lysyl oxidase-like 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis and other fibrotic conditions.
On Friday UK time Synairgen announced data from an in vivo preclinical model of lung fibrosis.
Refer to the Synairgen media release.
Categories: News and Media